Bijoy Hans Limited is an India-based company. The Company is mainly engaged in the business of trading in bulk drugs, pharmaceuticals, cosmetics and investment. The Company offers various pharmaceutical formulations, such as tablets, capsules, syrups, suspension and powders, focusing on segments, such as Antibiotics, Cough/ Cold/ Allergy. H-1 Receptor Antagonist (Antiulcerant), Nutraceuticals and NSAIDS.
BIJOY HANS LTD. Financial Highlights
- Revenue: BIJOY HANS LTD. reported revenue of ₹0.17 crore in FY26 vs ₹0.47 crore in FY25. It showed a decrease of 63.83% on a yearly basis.
- Operating Profit: BIJOY HANS LTD. reported an operating loss of ₹1.20 crore in FY26 vs ₹0.19 crore in FY25. It showed a decrease of 731.58% on a year-on-year basis.
- Net Profit: BIJOY HANS LTD. reported a net loss of ₹1.20 crore in FY26 vs ₹0.14 crore in FY25. It showed a decrease of 957.14% on a yearly basis.
BIJOY HANS LTD. Quarterly Result Highlights
- BIJOY HANS LTD. reported revenue of ₹0.07 crore in Mar 2026, compared with ₹0.05 crore in Dec 2025, representing an increase of 40.00% on a quarter-on-quarter (QoQ) basis.
- BIJOY HANS LTD. reported an operating loss of ₹0.63 crore in Mar 2026, compared with ₹0.16 crore in Dec 2025, representing a decrease of 293.75% on a quarter-on-quarter (QoQ) basis.
- BIJOY HANS LTD. reported a loss of ₹0.63 crore in Mar 2026, compared with ₹0.16 crore in Dec 2025, reflecting a decrease of 293.75% on a QoQ basis.
- The earnings per share (EPS) of BIJOY HANS LTD. stood at ₹0.45 during Mar 2026.